Travatan Z
Travatan Z (travoprost ophthalmic solution) 0.004% is a sterile topical ophthalmic solution used to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is a prostaglandin analog that works by increasing the outflow of aqueous humor from the eye. It is formulated with a proprietary ionic buffered preservative system (soFzia) designed to be gentler on the ocular surface compared to traditional benzalkonium chloride preservatives.
Dosage by Body Weight
The recommended dosage is one drop in the affected eye(s) once daily in the evening. Dose should not exceed once daily, as more frequent administration may decrease the intraocular pressure-lowering effect. If other topical ophthalmic drugs are being used, they should be administered at least 5 minutes apart.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients below 16 years of age have not been established.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients below 16 years of age have not been established.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients below 16 years of age have not been established.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients below 16 years of age have not been established.
- Body Weight
- 16-20 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients below 16 years of age have not been established.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | N/A | Safety and effectiveness in pediatric patients below 16 years of age have not been established. |
| 5-7 kg | Not recommended | N/A | Safety and effectiveness in pediatric patients below 16 years of age have not been established. |
| 8-10 kg | Not recommended | N/A | Safety and effectiveness in pediatric patients below 16 years of age have not been established. |
| 11-15 kg | Not recommended | N/A | Safety and effectiveness in pediatric patients below 16 years of age have not been established. |
| 16-20 kg | Not recommended | N/A | Safety and effectiveness in pediatric patients below 16 years of age have not been established. |
Formulation
Purpose
Lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Generic Name
TravoprostScheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.